Pulminiq Survival Benefit May Be Due To Patient Imbalances, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Imbalance in numbers of single and double lung transplant patients could have driven survival difference, FDA says. The agency’s Pulmonary-Allergy Drugs Advisory Committee will review Chiron’s Pulminiq for lung transplant rejection on June 6.